Skip to main content

​
What you get

A ranked investigator list with paper counts, representative citations, recency, and region — built from the literature rather than from whoever your team already knows.

​
Who it’s for

Medical affairs selecting advisory boards and speakers, clinical operations shortlisting trial sites, and business development mapping who owns a space.
Consensus returns author names, not affiliations, institutions, or contact details. This produces a ranked name list you then join to a CRM, an institutional directory, or a trial registry. Treat it as the discovery step, not the whole workflow.

​
How it works

1

Sweep the indication widely

Fan out across the indication, its mechanisms, its endpoints, and its main comparators. Paginate — emerging investigators sit in the long tail, and the top 20 results only ever show you the established names.
2

Count authors across the deduplicated set

Tally every name, weighting by citation_count, recency, and sjr_best_quartile. Track first and last author positions separately where you can infer them: last author usually signals the lab, first author the person doing the work.
3

Rank twice

Once by lifetime output, once by output in the last 24 months. The two lists differ substantially, and the second is usually the more actionable — it tells you who is active now rather than who was.
4

Add geography

Use country to build per-region shortlists. A single global list is rarely what a regional medical team can act on.
5

Read one paper per name

Output volume is not fit. Check that their actual work matches the specific question before anyone gets contacted.

​
The API call

​
What to check before you trust it

  • Name ambiguity is the main failure. Common surnames merge distinct researchers, and the same person appears under several spellings. Verify anyone you plan to act on.
  • Volume rewards large consortia. Authors on big multi-site trials accumulate counts without being the intellectual lead. Weight last-author position where you can.
  • Check the recency split before using the lifetime list. Highly-cited historical names may have left the field entirely.
  • This is a discovery list, not a vetted one. Conflicts of interest, availability, and current affiliation all need checking elsewhere.

Monitor new research about a drug, device, or brand

Keep watching the space and the names in it.

Build a drug target validation dossier

Go deep on the science these investigators are publishing.

Best practices

Fan-out and merge, and the rest of the primitives.

All use cases

Browse the gallery by persona.